The GH Stack: CJC-1295 + Ipamorelin
Last updated: April 2026
By Scott Williams·Firefighter/Paramedic · 25+ Years
The GH Stack caught on because the idea is simple, but the biology behind it is actually pretty smart.
Your pituitary has more than one way to release growth hormone.
CJC-1295 without DAC presses one button. Ipamorelin presses another. Press both at the same time, and you can create a stronger GH pulse than either one produces alone.
And unlike some peptide combinations that feel like two popular names got stapled together, this one has a real pharmacology story behind it. The community did not invent the idea that GHRH and GHRP pathways work together. Researchers studying growth hormone secretion have known for a long time that those two pathways can be synergistic.
The honest caveat is just as important: there are no published human clinical outcomes trials showing that this specific stack improves body composition, recovery, sleep, or anti-aging markers in healthy adults.
The GH pulse logic is real. The clinical outcome claims are not proven. Both things can be true.
Where I am stating a fact, I am citing it. Where I am sharing my read on the research, I am saying that out loud.
Verified Source
Ascension Peptides
COA-verified · MZ Biolabs · US domestic
Use code BIOHACKING for 50% off your first order
We only recommend vendors that pass our COA standard. How we vet →
What the GH Stack actually is
CJC-1295 without DAC (Mod GRF 1-29)
Short-acting GHRH analog with a roughly 30-minute half-life. Produces a brief GH signal and clears quickly. This is the version the standard GH Stack is built around — not the long-acting DAC version.
Selective growth hormone secretagogue working through the ghrelin receptor (GHS-R1a). Known for stimulating GH with less cortisol and prolactin spillover than older GHRPs.
So the stack is not “two peptides doing the exact same thing.” It is two different receptor pathways aimed at the same output: a GH pulse.
My read: the GH Stack is one of the cleaner community protocols from a mechanism standpoint. It does not make the clinical claims proven, but the receptor logic is real.
Why two switches instead of one
Growth hormone release can be stimulated through more than one pathway.
The GHRH receptor pathway
The signal your hypothalamus naturally uses to tell the pituitary to release GH. CJC-1295 without DAC mimics that signal. Think of it as the body's classic GH-release instruction.
The ghrelin receptor pathway
Ghrelin is best known as a hunger hormone, but it also helps stimulate GH release. Ipamorelin mimics part of that signal selectively. Think of this as a second GH-release instruction from a different lane.
The synergy
When both pathways are activated together, the GH pulse can be larger than either pathway produces alone.
One pathway tells the pituitary, “release GH.” The other pathway tells the pituitary, “yes, release more GH.”
This is not the same kind of stack as BPC-157 + TB-500. The Wolverine Stack is two different repair angles. The GH Stack is two switches on the same system. That is why it feels tighter mechanistically.
Why pulsatility matters
The body does not release GH in a flat line all day. It releases GH in pulses, especially during deep sleep. That is why the community usually prefers CJC-1295 without DAC for this stack. The short-acting version fits the pulse concept better — it comes in, helps trigger the signal, and then clears.
What the individual research shows
The GH Stack is built from two separate research stories.
CJC-1295
Teichman et al. (2006) JCEM (PMID 16352683) studied CJC-1295 in healthy adults and found dose-dependent increases in GH and IGF-1. Ionescu and Frohman (2006) JCEM (PMID 17018654) found CJC-1295 elevated trough and mean GH secretion while preserving pulsatility.
Safety event
A Phase II clinical trial of CJC-1295 in lipodystrophy was halted after a participant death. FDA has also flagged serious adverse events including increased heart rate and systemic vasodilatory reaction.
Ipamorelin
Raun et al. (1998) Eur J Endocrinol (PMID 9849822) characterized Ipamorelin as a potent and selective GH secretagogue, with minimal cortisol and prolactin elevation. Beck et al. (2014), a Phase 2 trial in postoperative ileus, did not meet its primary endpoint.
The combination
There are no published human clinical outcomes trials testing CJC-1295 without DAC plus Ipamorelin for body composition, recovery, sleep, or anti-aging in healthy adults.
The synergy concept is real at the pharmacodynamic level. But the specific community stack is not clinically proven as an outcomes protocol. That distinction is everything.
What the community protocol looks like
Community-reported protocols — not endorsements.
- CJC-1295 without DAC: 100 mcg per dose
- Ipamorelin: 100 mcg per dose
- Route: subcutaneous injection
- Frequency: 1–3 times daily
- Timing: pre-bed dosing is the most common
- Cycle pattern: often 8–16 weeks on, followed by time off
The two peptides are often combined in the same injection. The pre-bed timing is not random — the body's largest natural GH pulse typically happens during the first part of deep sleep.
Community protocols only. Not validated medical dosing.
Hard avoidance categories: active or recent cancer, uncontrolled diabetes, untreated or significant sleep apnea, pregnancy or breastfeeding, and anyone under 18 or not past skeletal maturity.
The safety picture
This stack deserves a dedicated safety section because of the CJC-1295 side. The GH Stack is not in the same risk category as a topical cosmetic peptide. This is endocrine signaling.
CJC-1295-specific concerns
Phase II trial halted after a participant death. FDA has flagged serious adverse events including increased heart rate and systemic vasodilatory reaction.
IGF-1 and cancer
IGF-1 elevation is epidemiologically associated with several cancer types. That does not prove this stack causes cancer, but the question cannot be dismissed with long-term use.
Glucose metabolism
Growth hormone signaling can affect insulin sensitivity. Relevant for anyone with diabetes risk, metabolic syndrome, or poor glucose control.
Outcome claims are unproven
Better body composition, improved recovery, better sleep, and anti-aging effects have not been proven in controlled trials for this combination.
My read: Ipamorelin is the cleaner half of the stack. CJC-1295 is the part that makes the safety discussion heavier. That does not kill the stack concept. It just means the stack deserves more respect than casual “anti-aging peptide” marketing gives it.
The regulatory situation (April 2026)
CJC-1295 and Ipamorelin are both not FDA approved.
Both have been part of FDA's compounding-review conversation, including PCAC discussions around the October and December 2024 meetings.
WADA
CJC-1295 is explicitly prohibited under S2.2.4 as a GHRH analog. Ipamorelin is also explicitly prohibited under S2.2.4 as a growth hormone secretagogue. For tested athletes, the GH Stack is not a gray area.
The purity problem
The purity problem is sharper with stacks. One compound means one quality-control chain. Two compounds means two.
The CJC-1295 naming issue matters here.A vial labeled “CJC-1295” could be with DAC, without DAC, mislabeled, underdosed, or backed by a generic non-matching COA. If someone thinks they are using without DAC but actually has the with-DAC version, they are getting a much longer-acting GH signal than intended. That is not a minor labeling mistake — it changes the pharmacology of the protocol.
For both peptides, the COA checklist:
- Does the COA match the exact batch?
- Does mass spectrometry confirm identity?
- Is purity measured by HPLC?
- Is the testing from a real third-party lab?
- Are sterility and endotoxin addressed?
- Does the CJC-1295 COA specify with DAC or without DAC?
- Does the vendor avoid claims that contradict research-use-only labeling?
Bottom line
My honest read: the GH Stack is one of the most logical community protocols in the peptide world.
The two-switch idea is real pharmacology. CJC-1295 without DAC activates the GHRH receptor. Ipamorelin activates the ghrelin receptor. Both converge on GH release. Together, they can produce a stronger GH pulse than either pathway alone.
But the outcome gap is still real. Moving GH is pharmacodynamics. Proving better body composition, recovery, sleep, or anti-aging effects in healthy adults is clinical outcomes research. That has not been done for this specific stack.
The safety picture also deserves respect. The CJC-1295 Phase II trial event and FDA-flagged cardiovascular reactions put this stack in a more serious category than casual peptide marketing suggests.
Not hype. Not dismissal. A smart idea that still needs the kind of human outcome data it has not gotten yet.
Related Reading
Affiliate Disclosure: This page contains affiliate links. We only recommend vendors we have personally vetted for COA compliance. We may earn a commission at no extra cost to you.
Disclaimer
This page is informational and not medical advice. Biohacking Unlocked is not a medical resource. CJC-1295 and Ipamorelin are not FDA approved for any indication, and research-use products are commonly labeled “for research purposes only / not for human consumption.” Anyone considering peptides should talk with a qualified healthcare provider. See our full disclaimer.